PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1619320-2	1992	One hundred-fifty mg of CDDP/body was intraperitoneally administered while the usual systolic blood pressure was increased to 130-140% by AT-II.	cddp	24-28	angiotensinogen	Homo sapiens	138-143	
1619320-5	1992	This suggests that, during renal vasoconstriction induced by AT-II, the renal blood flow as well as renal uptake of CDDP was decreased.	cddp	116-120	angiotensinogen	Homo sapiens	61-66	
1619320-9	1992	The extreme vasoconstriction in the kidneys and other organs induced by AT-II might have protected these organs from the toxicities of CDDP despite the fact that STS infusion was delayed by 15 minutes after CDDP infusion.	cddp	135-139	angiotensinogen	Homo sapiens	72-77	
1619320-10	1992	STS infused immediately after the cessation of AT-II could neutralize the CDDP preventing the occurrence of toxicities.	cddp	74-78	angiotensinogen	Homo sapiens	47-52	
2506819-2	1989	Concentration of the anti-cancer drug (CDDP) was measured in the specimen of cancer tissue obtained following intra-arterial infusion of the drug with angiotensin II.	cddp	39-43	angiotensinogen	Homo sapiens	151-165	
2389950-3	1990	The extreme vasoconstriction in the kidney and other organs during AT-II induced hypertension would protect these organs from CDDP induced toxicities.	cddp	126-130	angiotensinogen	Homo sapiens	67-72	
2389950-4	1990	Furthermore, STS infused immediately after the cessation of AT-II could neutralize the CDDP preventing the occurrence of toxicities.	cddp	87-91	angiotensinogen	Homo sapiens	60-65	
2389950-5	1990	The elevating plasma levels of CDDP might be beneficial to enhance the anticancer effects of CDDP, since the blood flow in cancer tissue was increased during AT-II induced hypertension.	cddp	31-35	angiotensinogen	Homo sapiens	158-163	
2389950-5	1990	The elevating plasma levels of CDDP might be beneficial to enhance the anticancer effects of CDDP, since the blood flow in cancer tissue was increased during AT-II induced hypertension.	cddp	93-97	angiotensinogen	Homo sapiens	158-163	
20978160-10	2010	Angiotensin II induced VEGF production in CDDP-treated cells; however, the AT1R antagonist significantly inhibited the increase in VEGF.	cddp	42-46	angiotensinogen	Homo sapiens	0-14	
6439121-4	1984	Intra-arterial infusion of CDDP either alone or in combination with ADM or MMC seems to present an aggressive approach in dealing with other metastatic neoplasms without increasing toxicity, especially if intra-arterial angiotensin II is infused concomitantly.	cddp	27-31	angiotensinogen	Homo sapiens	220-234